Biocon FY27 plan: 5 US biosimilars, in-licensing

What Biocon is trying to do in FY27

Biocon is stepping up its hunt for biosimilar in-licensing opportunities as it prepares for multiple product launches in FY27. Chief Executive Officer and Managing Director Shreehas Tambe said the company wants to use its expanding global commercial footprint to strengthen therapy franchises rather than enter entirely new areas. The stated aim is to align business development with Biocon’s current portfolio and go-to-market strengths in key geographies. Management also signalled a strategic shift from what it has called the “preserve” phase to a “consolidate” phase in FY27, with the major investment cycle largely behind it. That change in emphasis puts utilisation of built capacity, margin improvement, and better return on capital employed at the centre of the plan. Alongside biosimilars, the company is positioning for GLP-1 opportunities outside India, where it expects better margins and less crowded competition.

In-licensing: disciplined criteria and the Etanercept template

Tambe said Biocon has a dedicated business development team scouting for synergistic biosimilar assets. The company’s filter is described as disciplined: it wants products that “complement existing therapy areas” and fit its commercial strategy. Etanercept was cited as a template for how Biocon approaches in-licensing. The company did not develop the product in-house, but brought it in because it completed the portfolio and aligned with its strategy in specific franchises. Management said it will continue to look for similar bolt-on opportunities.

Why the strategy is shifting from “preserve” to “consolidate”

Biocon’s management described the next phase as one where previously built capabilities and capacity must translate into operating leverage. With the “major investment cycle” now largely behind it, the focus shifts to improving utilisation and expanding margins. Tambe also linked the new phase to a steady improvement in return on capital employed, implying a greater emphasis on disciplined deployment of resources. The thesis is that new launches can lift revenues, while costs are not expected to rise proportionately. That, in turn, is expected to support EBITDA margin expansion over the mid- to long-term. Management also pushed back on the idea of Biocon being only a low-cost manufacturer, positioning the business as a scaled global player with a broader capability set.

FY27 launch cycle: 5 US biosimilars in 12 months

A multi-product launch cycle is expected to be the key revenue driver in FY27, with a more pronounced impact anticipated in the second half. Tambe said five biosimilar launches are expected in the US alone over the next 12 months. Biocon’s biosimilar to Stelara, Yesintek (ustekinumab), has already scaled to nearly 20% market share in the US, which Tambe described as nearly a fifth of the market. Insulin Aspart, branded Kirsty, has launched in closed-door networks and is expected to expand into commercial payer channels in the second half. Aflibercept biosimilar Yesafili is expected to enter the US market in the second half of FY27, and Bevacizumab is also expected to start driving sales around the same time. Management’s stated priority is not only market share growth, but “sustainable margins and profitable growth.”

Profitability: biosimilar margins and operating leverage

Biocon reported biosimilar EBITDA margins of 26% in Q4FY26, with full-year biosimilar EBITDA margin also at 26%. Management said the full-year margin was up by 40% on a like-to-like basis. In a separate quarterly disclosure cited in the provided information, biosimilars revenue in Q3FY26 rose 9% year-on-year to ₹2,497 crore and EBITDA jumped 44% to ₹700 crore, implying a margin of 28%. Tambe said there is “no reason why margins should not improve” over time, arguing that new product launches should not require proportionate cost increases. Prioritising shipments to higher-margin geographies was also described as a driver of stronger profitability in a quarter where EBITDA contribution rose.

Interest-cost savings: ₹300+ crore tailwind below EBITDA

A key profitability tailwind highlighted by management is interest cost reduction following the buyout of minority shareholders in Biocon Biologics. The company expects over ₹300 crore of interest savings to flow through the profit and loss account on a full-year basis in FY27. Management noted that this benefit sits below the EBITDA line, which means it is expected to support profit before tax and net profit rather than EBITDA itself. At a consolidated level, Biocon delivered about 200 basis points of EBITDA margin expansion in FY26 on a like-to-like basis, driven by improved mix and operational excellence.

GLP-1 strategy: liraglutide momentum, semaglutide timing

On GLP-1 opportunities, Tambe said the initial market response to generic liraglutide in the US has been positive. Biocon received US FDA approval for generic Liraglutide (gVictoza) in March 2026, covering both diabetes and weight management indications. With semaglutide generics locked out of the US market until 2032, Tambe said there is a window in obesity indications, where reimbursement for branded semaglutide remains limited. Kiran Mazumdar-Shaw, Executive Chairperson, said Biocon is looking beyond India and sees the opportunity in the US and emerging markets, adding that biosimilars are expected to be a key growth driver. She also said semaglutide patents in India expired on March 20, with over 20 Indian drugmakers already in the market with generic versions. Biocon has filed semaglutide in Canada, Brazil, Saudi Arabia and Turkey, and is continuing filings in other markets, while India is “not on the immediate list” though regulatory processes are underway.

Generics and portfolio mix: biosimilars dominate revenue share

The provided information said biosimilars contribute 58% of Biocon’s total revenue, compared with 19% from generics and 23% from research services. For the generics business, Biocon reported a full-year EBITDA margin of 5% on revenues of ₹3,168 crore, with revenues up 17% year-on-year on a like-to-like basis. Tambe said a return to double-digit EBITDA margin is expected as utilisation of recently commissioned facilities improves. In the biosimilars business, Biocon Biologics posted full-year revenue of ₹9,017 crore in FY25, with 15% year-on-year growth. The same data set also noted that four biosimilars recorded sales of $10 crore each during the year (equivalent to $100 million each).

Oncology and pipeline disclosures: larger targets, longer cycle

In the US, Biocon has launched denosumab biosimilars with interchangeable designation, targeting a reference product that recorded around $100 crore in US sales in 2024. The company also secured a US market entry date no later than the second half of 2026 for Yesafili (aflibercept) after a settlement with Regeneron. Biocon disclosed three new oncology biosimilar assets: trastuzumab subcutaneous, nivolumab and pembrolizumab, targeting reference products Herceptin SC, Opdivo and Keytruda respectively. These reference therapies together generated over $1,000 crore in global sales in 2024, according to the provided information. Biocon estimates its oncology pipeline addresses an opportunity of over $1,500 crore, and said over 40 biologics are expected to go off patent by 2032, representing a cumulative opportunity of over $16,000 crore.

Key numbers and milestones

What this means for investors and the sector

Biocon’s near-term narrative is centred on execution of a crowded launch calendar, especially in the US, while protecting profitability through mix and operating leverage. The company is also explicitly linking capital-cycle normalisation to better returns, a message that typically matters to investors tracking margin and cash-flow quality. Interest-cost savings of over ₹300 crore in FY27 add a measurable support to earnings below EBITDA, assuming the savings flow through as guided. At the same time, Biocon’s GLP-1 plan reflects a preference for global markets, while acknowledging the intense competition in India after semaglutide patent expiry. In biosimilars, the disclosed oncology pipeline and market-sizing figures underline the longer-cycle opportunity, even as near-term performance will be judged on launches such as Yesintek, Kirsty, Yesafili and Bevacizumab.

Conclusion

Biocon is entering FY27 with two parallel priorities: expand its biosimilars portfolio through disciplined in-licensing, and execute a multi-product launch cycle led by the US market. Management expects operating leverage and interest-cost savings to support profitability as the capex-heavy phase eases. The next set of milestones investors will track include second-half FY27 launches and ramps, expansion of Kirsty into broader payer channels, and progress on semaglutide filings and commercial plans across international markets.